IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) (B.1.494)

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-COV2) (B.1.494) 

Summary

• SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.494): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain B.1.494 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike A262S, Spike D614G, Spike D796Y, Spike H49Y, Spike L452R, Spike N501Y, Spike P681R, Spike Q613H Size: 25 X 200 µL ~100 wells/96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications.

Overview

Properties

• Form: Liquid
• Formulation: Available upon request
• Storage: -80°C
• Concentration: 1X Concentrated

MSE Supplies is an authorized distributor of IBT Bioservices products.